Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Early antibiotic use in VLBW preemies ups risk of death, NEC, late-onset sepsis

02 Dec 2018

Antibiotic therapy in preterm, very low birth weight (VLBW) infants within the first 14 postnatal days increases the risk of subsequent late-onset sepsis, necrotizing enterocolitis (NEC) or death, a recent study has shown.

Researchers retrospectively assessed 374 VLBW preterm infants (53 percent male; median birth weight, 1,130 grams) admitted to the neonatal intensive care unit. Mean antibiotic exposure was 8.8±6 days of therapy, with 39 percent (n=145) receiving at least 5 calendar days of antibiotic therapy.

Seventy infants (19 percent) developed the composite outcome of late-onset sepsis (14 percent; n=52), NEC (6 percent; n=24) or death (3 percent; n=11). Median age at composite development was 29 days (sepsis: 29 days; NEC: 35 days; death: 31 days).

Multivariable logistic regression models showed that each day-of-therapy of antibiotic medication during the first 2 weeks of life was associated with an increased subsequent risk of the composite outcome (odds ratio [OR], 1.24; 95 percent CI, 1.17–1.31).

Similar risk patterns emerged when infants were stratified by gestational age (296/7 weeks: OR, 1.20; 1.12–1.29; 300/7 weeks: OR, 1.30; 1.17–1.43).

When length of therapy was instead used, researchers still found an increased risk of the composite outcome per additional day of exposure (OR, 1.47; 1.32–1.64). Receiver operating characteristic analysis showed that both measures of exposure provided similar and good areas under the curve.

The findings indicate that use of antibiotics in infants without proven infection should be carefully considered, as the associated risks can be significant, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.